SLNSW-Custirsen (OGX-011) combined with cabazitaxel and...-TN_cdi_proquest_miscellaneous_1951568623

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial

Full title: Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial

Author/creator: Beer, Tomasz M, Hotte, Sebastien J, Saad, Fred, Alekseev, Boris, Matveev, Vsevolod, Fléchon, Aude, Gravis, Gwenaelle, Joly, Florence, Chi, Kim N, Malik, Zafar, Blumenstein, Brent, Stewart, Patricia S, Jacobs, Cindy A, Fizazi, Karim.

Call Numbers:

Record Identifier: TN_cdi_proquest_miscellaneous_1951568623

Language: English

Formats: Articles

Publishers: England: Elsevier Ltd

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1951568623

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial

    Record identifier

    TN_cdi_proquest_miscellaneous_1951568623

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1951568623

    Share

    Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1951568623

    Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial

    Full title

    Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial

    Author / Creator

    Beer, Tomasz M ; Hotte, Sebastien J ; Saad, Fred ; Alekseev, Boris ; Matveev, Vsevolod ; Fléchon, Aude ; Gravis, Gwenaelle ; Joly, Florence ; Chi, Kim N ; Malik, Zafar ; Blumenstein, Brent ; Stewart, Patricia S ; Jacobs, Cindy A ; Fizazi, Karim

    Publisher

    England: Elsevier Ltd

    Journal title

    The lancet oncology, 2017, Vol.18 (11), p.1532-1542

    Record Identifier

    TN_cdi_proquest_miscellaneous_1951568623

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Aged Analysis Antimitotic agents Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis Cancer therapies Care and treatment Castration Chemotherapy Clinical trials Corticosteroids Disease-Free Survival Dose-Response Relationship, Drug Drug Administration Schedule Drug dosages Humans Internationality Kaplan-Meier Estimate Male Maximum Tolerated Dose Medical prognosis Metastases Metastasis Middle Aged Neoplasm Invasiveness - pathology Neoplasm Staging Pain Prednisone Prednisone - administration & dosage Product development Prognosis Proportional Hazards Models Prospective Studies Prostate cancer Prostatic Neoplasms, Castration-Resistant - diagnostic imaging Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - mortality Proteins Steroids Survival Analysis Taxoids - administration & dosage Thionucleotides - adverse effects Thionucleotides - therapeutic use Tomography, X-Ray Computed - methods Treatment Outcome Working groups

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_miscellaneous_1951568623

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1951568623

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections